Small transpacific team led by Lilly, Everest vet turns to computational tools for next wave of peptide drug discovery

When Ker­ry Blan­chard left Ever­est Med­i­cines in Au­gust 2022 to make room for a CEO with a com­mer­cial back­ground, he didn’t have a full idea of what he was do­ing next. But hav­ing spent the past decade in drug de­vel­op­ment, the sci­en­tist and physi­cian by train­ing, knew the di­rec­tion he want­ed to go.

“I’ve been very in­ter­est­ed in mov­ing back in­to dis­cov­ery,” Blan­chard said.

A few months lat­er, he jumped right in with a new start­up, Per­pet­u­al Med­i­cines, that’s fo­cused on ap­ply­ing com­pu­ta­tion­al meth­ods to pep­tide ther­a­pies, which he be­lieves will be the fastest-grow­ing area in phar­ma over the next 20 years. Now, Blan­chard, the co-founder and CEO, is tak­ing the wraps off a $8 mil­lion seed round led by Cheng­wei Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.